CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
LY2835219drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02059148
NCT02059148Phase 1Completed

Effect of Food on the Pharmacokinetics of LY2835219 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Feb 11, 2014·Updated Jan 7, 2019

In Brief

A Phase 1 clinical trial evaluating LY2835219 for Healthy Volunteers. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Participants in this study will receive 3 single oral doses of LY2835219 at least 14 days apart. One dose will be given with a standard meal, one dose with a high-fat meal and one dose without food. The study will evaluate the effects of the standard and high-fat meals on how much drug gets into the bloodstream. Side effects will be documented. This study is approximately 43 days, not including screening. Screening is required within 28 days prior to the start of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 11, 2014
Enrollment StartFeb 1, 2014
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.4 years ago

Interventions

LY2835219drug

Administered orally.